- Home
- LPX vs APLS Comparison
LPX vs APLS Comparison
Compare LPX & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LPX | APLS |
|---|---|---|
| Founded | 1973 | 2009 |
| Country | United States | United States |
| Employees | N/A | 733 |
| Industry | Forest Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 5.2B |
| IPO Year | 1994 | 2015 |
Fundamental Metrics
Financial Performance| Metric | LPX | APLS |
|---|---|---|
| Price | $76.55 | $40.94 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 21 |
| Target Price | ★ $105.29 | $33.59 |
| AVG Volume (30 Days) | 1.0M | ★ 9.1M |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.59% | N/A |
| EPS Growth | N/A | ★ 112.50 |
| EPS | ★ 2.08 | 0.20 |
| Revenue | ★ $2,708,000,000.00 | $1,003,782,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11.23 | $18.19 |
| P/E Ratio | ★ $36.26 | $204.63 |
| Revenue Growth | N/A | ★ 28.46 |
| 52 Week Low | $68.87 | $16.10 |
| 52 Week High | $102.86 | $40.95 |
Technical Indicators
Market Signals| Indicator | LPX | APLS |
|---|---|---|
| Relative Strength Index (RSI) | 53.46 | 87.20 |
| Support Level | $74.00 | $19.29 |
| Resistance Level | $76.79 | $40.95 |
| Average True Range (ATR) | 2.91 | 0.08 |
| MACD | 0.56 | -0.53 |
| Stochastic Oscillator | 84.96 | 96.77 |
Price Performance
Historical ComparisonAbout LPX Louisiana-Pacific Corporation
Louisiana-Pacific Corp is an oriented strand board producer and also offers engineered wood siding used in home construction and repair and remodel projects. The Siding business of the company serves different markets with a broad product portfolio of engineered wood siding, trim, soffit, and fascia. The Company operates through three operating segments: Siding, OSB, and LP South America (LPSA). The company generates majority of its revenue from siding segment.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).